RE:RE:RE:RE:rareTRX is a strange one for sure. When TRX signed their deal with Novartis, the stock headed lower into a month long decline, which was baffling to say the least. Only after they released their double digit Q3 numbers did the stock start to move northward, and even then, I think (from memory) it was 2 or 3 days before the market took notice of those numbers. This was before 6M shares were traded in a 48 hours period though, and as a previous poster had stated, this stock is starting to get wound pretty tight. Most buyers - I think - have dug in their heels and most sellers are playing TRX for short term profit. Wherever the shares trade at between now and Q4 numbers/next licensing deal, is just noise. I'm calling $1.50 before the snow melts followed by the inevitable overrshoot to $2.50, followed then by a pullback back to $1.75 - and then a normalization. But who knows.